We are live on ! Find out more

BBLG

Bone Biologics

BBLG

Market cap $1.54M

0.5602 USD

-0.0082

1.44%

At close Updated Sep 8, 1:09 PM EDT

1 day

-1.44%

5 days

-0.59%

1 month

-36.31%

3 months

-55.18%

6 months

-54.08%

Year to date

-63.62%

1 year

-73.94%

5 years

-99.99%

10 years

-99.99%

About: Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.

Employees: 2

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Bone Biologics Expands Trial Sites

BURLINGTON, MA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced that six hospital sites in Australia are now under agreement to participate in its first-in-human pilot clinical trial of NB1, the Company's rhNELL-1-based bone graft product for spinal fusion.

Bone Biologics Expands Trial Sites

Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

BURLINGTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.

Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1

BURLINGTON, Mass, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announces that the validated shelf life of its rhNELL-1 protein has been extended to 32 months. “Reaching a 32-month validated shelf life gives us greater flexibility in how we manufacture, store and distribute rhNELL-1 as we prepare for pivotal-study scale,” said Jeff Frelick, Chief Executive Officer.

Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1

Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities

BURLINGTON, Mass, July 23, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) ("Bone Biologics" or the "Company"), a developer of orthobiologic products for spine fusion markets, today issued a shareholder update summarizing the Company's progress through the first half of 2026, including its recently completed financing, continued advancement of NB1, its rhNELL-1-based bone graft product candidate, and further validation of its manufacturing and product stability profile. “During the first half of 2026, we strengthened several of the fundamental drivers underlying NB1's development and long-term value proposition: clinical execution, product stability, intellectual property protection and capital visibility,” said Bone Biologics CEO Jeff Frelick.

Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities

Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants in cash $3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrants in cash

Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1

BURLINGTON, Mass, May 19, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announces that the validated shelf life of its rhNELL-1 protein product has been further extended to 29 months, building on the 24-month milestone the Company reported in December 2025. The updated shelf life is supported by continued third-party stability data.

Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1

Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook

Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq compliance Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq compliance

Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook

Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months

Milestone advances manufacturing readiness and supports long-term commercialization strategy Milestone advances manufacturing readiness and supports long-term commercialization strategy

Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive Officer Jeffrey Frelick has issued the following letter to stockholders. To My Fellow Stockholders: I am pleased to provide a progress report on Bone Biologics' development of NB1 and to review our expected milestones for the coming year, including the anticipated com.

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference

BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, President and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025. Management will be available during the conference for in-person and virtual one-on-one meetings. Institutional investors and in.

Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference

See News Rankings

Price charts implemented using Lightweight Charts™